Anti-VISTA antibodies or antigen-binding fragments thereof and uses thereof
Anti-VISTA antibodies or their antigen-binding fragments obtained through screening of a fully human antibody library have solved the problem of low efficiency of anti-VISTA antibodies in existing technologies, achieving efficient binding to human VISTA antigens and endocytosis of target cells, thus enhancing the efficacy of tumor immunotherapy.
Patent Information
- Application Number
- CN202411001242.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-07-28
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-25
AI Technical Summary
The lack of highly effective antibodies against human T cell activation V domain Ig inhibitors (VISTA) in current technologies makes it impossible to effectively target T cell immunosuppression, resulting in poor efficacy of tumor immunotherapy.
Anti-VISTA antibodies or their antigen-binding fragments obtained by screening a fully human antibody library contain specific complementarity-determining region (CDR) sequences and human framework region amino acid sequences. They have high affinity and specificity, and can bind to human VISTA antigens and be endocytosed by target cells.
It achieves efficient binding and target cell endocytosis with human VISTA antigen, enhancing the immune activation effect on T cells and showing potential applications in tumor immunotherapy.
Smart Images

Figure CN118515760B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biopharmaceutical technology, and in particular to an anti-VISTA antibody or an antigen-binding fragment thereof and uses thereof.
[0002] Sequence listing submitted simultaneously
[0003] The entire contents of the following XML file are incorporated herein by reference in their entirety: Computer Readable Form (CRF) of Sequence Listing (File Name: TFH01055PCT-sequence listing.TXT, Date: 20240617, Size: 57.8 KB). Background Art
[0004] V-domain Ig inhibitor of T cell activation (VISTA) is a new immunoregulatory receptor and a member of the B7 family that maintains the homeostasis of T cells and myeloid cells. It has a high homology with PD-L1 but a different mechanism of action. VISTA is widely expressed on myeloid and lymphocytes and is often considered an indicator of poor prognosis in a variety of cancers. Importantly, VISTA's antibody targeting acts on both innate immunity and adaptive immunity. The widespread expression of VISTA gives it higher non-redundant activity than other immune checkpoints, making VISTA a very promising target for tumor immunotherapy.
[0005] VISTA is an immunomodulatory receptor expressed on most cell subsets of the hematopoietic lineage. Myeloid cells have the highest expression, with significantly increased expression levels in microglia and neutrophils. Other myeloid subsets, including monocytes, macrophages, basophils, and dendritic cells, follow. Unlike other checkpoints that are induced at different stages after activation, VISTA is expressed in a steady-state form on these subsets.
[0006] On lymphocytes, VISTA is most highly expressed on naive CD4+T cells and FoxP3+T regulatory cells (Tregs). It is expressed at lower levels on CD8+T cells, natural killer cell subsets, and thymocytes. Although VISTA is not expressed on B cells, it is significantly expressed on plasma cells. It is also worth noting that the study found that reduced expression of VISTA was detected under inflammatory conditions. In animal models of preclinical studies, gene knockout or antibody blocking of VISTA can activate T cell responses to tumor cells.
[0007] Clear scientific evidence shows that VISTA is a ligand that can induce deep T cell suppression. Various groups, including Dartmouth College and Jannsen, have reported a variety of antagonistic anti-human VISTA antibodies. Such antibodies can be used to treat conditions such as cancer where it is desired to suppress the immunosuppressive effects of VISTA on T cell immunity. Summary of the invention
[0008] Based on the existing technology, the present application uses a fully human antibody library to screen and obtain a new type of anti-human T cell activated V domain Ig inhibitory factor (VISTA) antibody, which can bind to the human VISTA antigen and show high antibody affinity.
[0009] The specific technical solutions of this application are as follows:
[0010] The present application provides an anti-VISTA antibody or an antigen-binding fragment thereof, comprising a complementary determining region (CDR) sequence selected from the following: SEQ ID NO: 2-37, or comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the complementary determining region sequence, respectively, wherein the complementary determining region is determined based on the Kabat numbering system.
[0011] Preferably, for the anti-VISTA antibody or antigen-binding fragment thereof described above, wherein the complementarity determining region comprises a heavy chain complementarity determining region and a light chain complementarity determining region;
[0012] Wherein, the heavy chain complementarity determining region is:
[0013] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:2, a CDR2 having an amino acid sequence as shown in SEQ ID NO:3, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:4;
[0014] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:8, a CDR2 having an amino acid sequence as shown in SEQ ID NO:9, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:10;
[0015] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 14, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 15, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 16;
[0016] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:20, a CDR2 having an amino acid sequence as shown in SEQ ID NO:21, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:22;
[0017] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:26, a CDR2 having an amino acid sequence as shown in SEQ ID NO:27, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:28; or
[0018] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:32, a CDR2 having an amino acid sequence as shown in SEQ ID NO:33, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:34; and
[0019] Wherein, the light chain complementary determining region is
[0020] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:5, a CDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:7;
[0021] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 11, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 12, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 13;
[0022] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 17, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 18, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 19;
[0023] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:23, a CDR2 having an amino acid sequence as shown in SEQ ID NO:24, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:25;
[0024] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:29, a CDR2 having an amino acid sequence as shown in SEQ ID NO:30, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:31; or
[0025] It comprises a CDR1 with the amino acid sequence shown in SEQ ID NO:35, a CDR2 with the amino acid sequence shown in SEQ ID NO:36, and a CDR3 with the amino acid sequence shown in SEQ ID NO:37.
[0026] Preferably, the above-mentioned antibody or antigen-binding fragment thereof comprises the following heavy chain complementary determining regions and light chain complementary determining regions:
[0027] (1) the heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:2, CDR2 of the amino acid sequence shown in SEQ ID NO:3, and CDR3 of the amino acid sequence shown in SEQ ID NO:4, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:5, CDR2 of the amino acid sequence shown in SEQ ID NO:6, and CDR3 of the amino acid sequence shown in SEQ ID NO:7;
[0028] (2) the heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:8, CDR2 of the amino acid sequence shown in SEQ ID NO:9, and CDR3 of the amino acid sequence shown in SEQ ID NO:10, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:11, CDR2 of the amino acid sequence shown in SEQ ID NO:12, and CDR3 of the amino acid sequence shown in SEQ ID NO:13;
[0029] (3) the heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:14, CDR2 of the amino acid sequence shown in SEQ ID NO:15, and CDR3 of the amino acid sequence shown in SEQ ID NO:16, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:17, CDR2 of the amino acid sequence shown in SEQ ID NO:18, and CDR3 of the amino acid sequence shown in SEQ ID NO:19;
[0030] (4) the heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:20, CDR2 of the amino acid sequence shown in SEQ ID NO:21, and CDR3 of the amino acid sequence shown in SEQ ID NO:22, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:23, CDR2 of the amino acid sequence shown in SEQ ID NO:24, and CDR3 of the amino acid sequence shown in SEQ ID NO:25;
[0031] (5) the heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:26, CDR2 of the amino acid sequence shown in SEQ ID NO:27, and CDR3 of the amino acid sequence shown in SEQ ID NO:28, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:29, CDR2 of the amino acid sequence shown in SEQ ID NO:30, and CDR3 of the amino acid sequence shown in SEQ ID NO:31; or
[0032] (6) The heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:32, CDR2 of the amino acid sequence shown in SEQ ID NO:33, and CDR3 of the amino acid sequence shown in SEQ ID NO:34, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:35, CDR2 of the amino acid sequence shown in SEQ ID NO:36, and CDR3 of the amino acid sequence shown in SEQ ID NO:37.
[0033] Preferably, the antibody or antigen-binding fragment thereof described in any one of the above items comprises a human framework region amino acid sequence, and preferably, the human framework region amino acid sequence is a human consensus framework region amino acid sequence.
[0034] Preferably, the antibody or antigen-binding fragment thereof described in any of the above items comprises a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence selected from the following: SEQ ID NO: 38-49, or comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the heavy chain variable region amino acid sequence and the light chain variable region amino acid sequence, respectively.
[0035] Preferably, for the above-mentioned antibody or antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:38, the amino acid sequence shown in SEQ ID NO:40, the amino acid sequence shown in SEQ ID NO:42, the amino acid sequence shown in SEQ ID NO:44, the amino acid sequence shown in SEQ ID NO:46, the amino acid sequence shown in SEQ ID NO:48, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence, respectively; and / or
[0036] The light chain variable region comprises the amino acid sequence shown in SEQ ID NO:39, the amino acid sequence shown in SEQ ID NO:41, the amino acid sequence shown in SEQ ID NO:43, the amino acid sequence shown in SEQ ID NO:45, the amino acid sequence shown in SEQ ID NO:47, the amino acid sequence shown in SEQ ID NO:49, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence, respectively.
[0037] Preferably, for the above-mentioned antibody or antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:38 and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:39, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence, respectively;
[0038] the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:40 and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:41, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence, respectively;
[0039] the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:42 and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:43, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence, respectively;
[0040] the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:44 and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:45, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence, respectively;
[0041] The heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:46 and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:47, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence, respectively; or
[0042] The heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:48, and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:49, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence, respectively.
[0043] Preferably, the antibody or antigen-binding fragment thereof described in any of the above items is a monoclonal antibody, a recombinant antibody, a fully human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody or an antigen-binding fragment thereof.
[0044] Preferably, with respect to the above-mentioned antibody or antigen-binding fragment thereof, the antigen-binding fragment is a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment or a scFv fragment.
[0045] Preferably, for any of the above antibodies or antigen-binding fragments thereof, the antibody or antigen-binding fragment thereof comprises the constant domain of human IgG1, IgG2, IgG3 or IgG4.
[0046] The present application provides a polynucleotide encoding the antibody or antigen-binding fragment thereof described in any one of the above items.
[0047] The present application provides an expression vector, which comprises the polynucleotide described above.
[0048] The present application provides a host cell, which comprises the expression vector described above. Preferably, the host cell is a prokaryotic cell or a eukaryotic cell.
[0049] The present application provides a method for preparing any of the above antibodies or antigen-binding fragments thereof, comprising:
[0050] (a) culturing the host cell according to the above; and
[0051] (b) recovering the antibody or antigen-binding fragment thereof from the cultured host cells.
[0052] The present application provides a pharmaceutical composition, which comprises any of the antibodies or antigen-binding fragments thereof described above and a pharmaceutically acceptable excipient.
[0053] The present application provides a conjugate comprising any one of the antibodies or antigen-binding fragments thereof described above.
[0054] The present application provides a fusion protein comprising any of the antibodies or antigen-binding fragments thereof described above.
[0055] The present application provides a method for treating a subject suffering from a VISTA-mediated disease, the method comprising administering to the subject an effective amount of any one of the above-described antibodies or antigen-binding fragments thereof, the above-described pharmaceutical composition, the above-described conjugate, or the above-described fusion protein.
[0056] Preferably, in the above-described method, the VISTA-mediated related disease is leukemia, lymphoma, myelodysplasia, myeloma or a combination thereof.
[0057] The present application provides the use of any of the above-mentioned antibodies or antigen-binding fragments thereof, the above-mentioned pharmaceutical compositions, the above-mentioned conjugates, or the above-mentioned fusion proteins in the preparation of drugs for treating VISTA-mediated related diseases.
[0058] The present application provides the use of any of the above-mentioned antibodies or antigen-binding fragments thereof, the above-mentioned pharmaceutical compositions, the above-mentioned conjugates, or the above-mentioned fusion proteins in the treatment of VISTA-mediated related diseases.
[0059] Preferably, for the above-mentioned use, the VISTA-mediated related disease is leukemia, lymphoma, myelodysplasia, myeloma or a combination thereof.
[0060] Effects of the Invention
[0061] The antibodies or antigen-binding fragments thereof described in the present application can bind to the human VISTA antigen, have high binding activity, and can be internalized by target cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1A This is the SDS-PAGE electrophoresis purity diagram of the anti-VISTA antibody.
[0063] Figure 1B This is the SEC-HPLC chromatographic purity chart.
[0064] Figure 2 This is the ELISA binding activity detection diagram of anti-VISTA antibodies.
[0065] Figure 3A This is a flow cytometry fluorescence sorting detection diagram of HL-60 cells incubated with fluorescently labeled anti-VISTA antibody for 1 hour.
[0066] Figure 3B This is a flow cytometry fluorescence sorting detection diagram of HL-60 cells incubated with fluorescently labeled anti-VISTA antibodies for 24 hours.
[0067] Figure 4This is a fluorescence microscopy image of HL-60 cells incubated with fluorescently labeled anti-VISTA antibody for 24 hours. DETAILED DESCRIPTION
[0068] The present application is described in detail below in conjunction with the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided to enable a more thorough understanding of the present application and to enable the scope of the present application to be fully communicated to those skilled in the art.
[0069] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the functional differences of components as the criterion for distinction. As mentioned throughout the specification and claims, "including" or "comprising" are open-ended terms and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is based on the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims.
[0070] definition
[0071] As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to a specific antigen or is immunoreactive to a specific antigen. Antibodies may include, for example, polyclonal, monoclonal, and genetically engineered antibodies and antigen-binding fragments thereof. Antibodies may be, for example, mouse antibodies, chimeric antibodies, humanized antibodies, heterologous conjugate antibodies, bispecific antibodies, diabodies, triabodies, or tetrabodies.
[0072] As used herein, the term "antigen binding fragment" refers to a region of a molecule that specifically binds to an antigen. An antigen binding domain can be an antigen binding portion of an antibody or an antigen binding fragment thereof. An antigen binding fragment can include, for example, Fab', F(ab')2, Fab, Fv, rIgG, scFv, hcAb (heavy chain antibody), single domain antibody, VHH, VNAR, sdAb or nanobody.
[0073] As used herein, the term "variable region" refers to the variable region of an antibody light chain or the variable region of an antibody heavy chain, either alone or in combination. As known in the art, the variable regions of the heavy and light chains are each composed of four framework regions (FRs) connected by three complementarity determining regions (CDRs), also referred to as hypervariable regions. The CDRs in each chain are kept close together by the FRs, and together with the CDRs from the other chains, contribute to the formation of the antigen binding site of the antibody.
[0074] As used herein, the term "identity" refers to the number of identical nucleotide or amino acid positions shared by different sequences (i.e., identity = # of identical positions / # of total positions × 100), taking into account the number of gaps that need to be introduced to obtain optimal alignment and the length of each gap. The percentage identity between two nucleotide or amino acid sequences can be determined, for example, using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11-17 (1988), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weighted residue table, a gap length penalty of 12, and a gap penalty of 4.
[0075] As used herein, the term "human consensus framework region" is a framework representing the amino acid residues most commonly present in a selection of human immunoglobulin VL or VH framework sequences. In general, human immunoglobulin VL or VH sequences are selected from a subgroup of variable domain sequences. In general, a subgroup of sequences is a subgroup such as Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3. In one embodiment, for VL, the subgroup is subgroup κI as described by Kabat et al. (supra). In one embodiment, for VH, the subgroup is subgroup III as described by Kabat et al. (supra).
[0076] As used herein, the term "monoclonal antibody" means an antibody derived from a population of substantially homogeneous antibodies, that is, the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may be present in minute amounts. Monoclonal antibodies are highly specific for a single antigenic site. In addition, unlike polyclonal antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody is directed to a single determinant on the antigen. The modifier "monoclonal" indicates that the antibody is derived from a substantially homologous antibody population, and should not be construed as requiring the antibody to be produced by any ad hoc method.
[0077] As used herein, the term "chimeric antibody" refers to an antibody in which part or all of the variable region amino acid sequence is derived from one species and the constant region sequence is derived from another species, for example, an antibody in which the variable region amino acid sequence is derived from a mouse antibody and the constant region sequence is derived from a human antibody.
[0078] As used herein, the term "humanized" antibody refers to a form of a non-human (e.g., murine) antibody that is a chimeric immunoglobulin, an immunoglobulin chain, or a fragment thereof containing minimal sequence derived from a non-human immunoglobulin (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of an antibody). Preferably, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from one or more CDRs of the recipient are replaced with residues from one or more CDRs of a non-human species (such as a mouse, rat, or rabbit) (donor antibody) having the desired specificity, affinity, and capacity.
[0079] As used herein, the term "multispecific antibody" refers to an antibody that binds to two or more different epitopes on at least two or more different targets, including bispecific, trispecific, tetraspecific, pentaspecific, hexaspecific, and the like.
[0080] As used herein, the term "conjugate" refers to a molecule coupled to another molecule. In the present application, the conjugate is a conjugate obtained by coupling the anti-VISTA antibody or antigen-binding fragment thereof described in the present application to another agent such as a small molecule drug. In the present application, there is no limitation on small molecule drugs, and those skilled in the art can make routine selections as needed.
[0081] As used herein, the term "fusion protein" refers to a substance obtained by combining an antibody with a substance via a non-peptide linker or a peptide linker, or directly combining. In the present application, the fusion protein refers to a substance obtained by combining the anti-VISTA antibody or its antigen-binding fragment with a substance via a non-peptide linker or a peptide linker, or directly combining. In the present application, for a substance and a non-peptide linker, the present application does not impose any restrictions, and those skilled in the art can make conventional selections as needed.
[0082] As used herein, "specifically binding" or antibodies, conjugates or polypeptides that are referred to as "preferentially binding" (used interchangeably herein) to a target or antigen (e.g., VISTA protein) are conventional technical terms in the art, and methods for determining such specific or preferential binding are also well known in the art. If a molecule reacts or binds to a specific cell or substance more often, more quickly, with a greater duration and / or with a greater affinity than an alternative cell or substance, the molecule is said to exhibit "specific binding" or "preferential binding". If an antibody binds with greater affinity, more easily and / or with a greater duration than other substances, then the antibody "specifically binds" or "preferentially binds" to a target or antigen. For example, an antibody that specifically or preferentially binds to a VISTA epitope is an antibody that binds to the epitope with greater affinity, avidity, more easily and / or with a greater duration than it binds to other VISTA epitopes or non-VISTA epitopes.
[0083] As used herein, the term "operably linked" means a functional connection between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or a binding site array for a transcriptional regulator) and another nucleic acid sequence, and enables the regulatory sequence to regulate the transcription and / or translation of the other nucleic acid sequence.
[0084] When prokaryotic cells are used as host cells, they usually contain a strong promoter capable of carrying out transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter or T7 promoter), a ribosome binding site for initiating translation, and a transcription / translation termination sequence. In addition, for example, when eukaryotic cells are used as host cells, they contain a promoter derived from the genome of a mammalian cell (e.g., a metallothionein promoter, a β-actin promoter, a human hemoglobin promoter, or a human muscle creatine promoter) or a promoter derived from a mammalian virus (e.g., an adenovirus late promoter, a vaccinia virus 7.5K promoter, an SV40 promoter, a cytomegalovirus (CMV) promoter, a HSV tk promoter, a mouse mammary tumor virus (MMTV) promoter, an HIV LTR promoter, a Moloney virus promoter, an Epstein-Barr virus (EBV) promoter, and a Rous sarcoma virus (RSV) promoter), and they generally have a polyadenylation sequence as a transcription termination sequence.
[0085] Optionally, the vector can be fused to another sequence to purify the antibody expressed therefrom. The sequence to be fused includes, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA), 6x His (six histidine; Qiagen, USA), etc. The vector includes antibiotic resistance genes generally used as selective markers in the art, and the resistance genes include: ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline.
[0086] As used herein, the term "administering" refers to parenteral, intravenous, intraperitoneal, intramuscular, intratumoral, intralesional, intranasal or subcutaneous administration to a subject in need thereof, oral administration, administration by suppository, topical contact, intrathecal administration, or implantation of a sustained release device, such as a mini-osmotic pump.
[0087] As used herein, "subject" refers to an individual who is at risk of a disease, disorder or condition or who suffers from the disease, disorder or condition, and the individual can be treated or improved by the antibody or its pharmaceutical composition described herein. In some embodiments, the antibody or its pharmaceutical composition of the present application is administered to the subject to treat the relevant disease.
[0088] As used herein, the term "treatment" refers to any intervention that results in any observable beneficial effect of treatment, or any statistically significant indicator of success in treating or ameliorating a disease or condition, such as improving the signs, symptoms, or progression of a disease or pathological condition. For example, a beneficial effect can be demonstrated by reducing the disease in a subject, delaying the onset of the disease, or reducing the severity of clinical symptoms of the disease, reducing the frequency with which a subject experiences symptoms of the disease, slowing the progression of the disease, reducing the number of relapses of the disease, improving the overall health of the subject, or by other parameters specific to a particular disease.
[0089] As used herein, the term "prevention" is treatment administered to a subject who does not show signs of a disease or who shows only early signs of the disease, with the goal of reducing the risk of developing the pathology or further progression of the early disease.
[0090] As used herein, the term "effective amount" or "effective dose" refers to an amount of an antibody or its pharmaceutical composition sufficient to achieve a desired (e.g., beneficial) effect in a subject receiving treatment with the antibody or its pharmaceutical composition, such as an amount sufficient to improve one or more symptoms of the disease being treated in a statistically significant manner, to delay the deterioration of a progressive disease in a statistically significant manner, or to prevent the onset of other related symptoms or diseases in a statistically significant manner, or any combination thereof. In some embodiments, the effective amount of an antibody or its pharmaceutical composition is an amount sufficient to inhibit or treat a disease, with minimal or no toxicity in the subject, excluding the presence of one or more adverse side effects. The effective amount or dose can be administered once or multiple times within a given time period. The effective amount or dose can depend on the purpose of the treatment, and can be determined by a person skilled in the art according to the needs of the subject. When referring to a single active ingredient administered alone, the effective amount or dose refers to the single ingredient. When referring to a combination, the effective amount or dose refers to the combined amount of active ingredients that produce a therapeutic effect, whether administered continuously or simultaneously.
[0091] Antibodies or antigen-binding fragments thereof
[0092] The present application provides an anti-VISTA antibody or antigen-binding fragment thereof, comprising a complementary determining region (CDR) sequence selected from the following: SEQ ID NO: 2-37, or comprising an amino acid sequence having at least 80% identity with the complementary determining region (CDR) sequence, wherein the complementary determining region is determined based on the kabat numbering system. In some embodiments, it comprises a human framework region amino acid sequence, preferably, the human framework region amino acid sequence is a human consensus framework region amino acid sequence. In some embodiments, it comprises a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence selected from the following: SEQ ID NO: 38-49, or comprising an amino acid sequence having at least 80% identity with the heavy chain variable region amino acid sequence and the light chain variable region amino acid sequence, respectively.
[0093] The amino acid sequence of SEQ ID NO:2 is as follows:
[0094] CDRH1:STGYSWS
[0095] The amino acid sequence of SEQ ID NO:3 is as follows:
[0096] CDRH2:NIYHSGSTYYNPSLES
[0097] The amino acid sequence of SEQ ID NO:4 is as follows:
[0098] CDRH3:QGGSSSSWYYYYMDV
[0099] The amino acid sequence of SEQ ID NO:5 is as follows:
[0100] CDRL1:SGSSSNIGNNYVS
[0101] The amino acid sequence of SEQ ID NO:6 is as follows:
[0102] CDRL2:DNNKRPS
[0103] The amino acid sequence of SEQ ID NO:7 is as follows:
[0104] CDRL3:GTWDSSLSAVV
[0105] The amino acid sequence of SEQ ID NO:8 is as follows:
[0106] CDRH1: SYAIS
[0107] The amino acid sequence of SEQ ID NO:9 is as follows:
[0108] CDRH2:GIIPIFGTANYAQKFQG
[0109] The amino acid sequence of SEQ ID NO: 10 is as follows:
[0110] CDRH3:ELGSTGAYYYYGMDV
[0111] The amino acid sequence of SEQ ID NO: 11 is as follows:
[0112] CDRL1:SGSSSNIGSNTVN
[0113] The amino acid sequence of SEQ ID NO: 12 is as follows:
[0114] CDRL2:SNNQRPS
[0115] The amino acid sequence of SEQ ID NO: 13 is as follows:
[0116] CDRL3:AAWDDSLSGWV
[0117] The amino acid sequence of SEQ ID NO: 14 is as follows:
[0118] CDRH1:GSAMH
[0119] The amino acid sequence of SEQ ID NO: 15 is as follows:
[0120] CDRH2:RIRSKANSYATAYAASVKG
[0121] The amino acid sequence of SEQ ID NO: 16 is as follows:
[0122] CDRH3: VNSGYYGPDY
[0123] The amino acid sequence of SEQ ID NO: 17 is as follows:
[0124] CDRL1:TRNGGSIASNYVQ
[0125] The amino acid sequence of SEQ ID NO: 18 is as follows:
[0126] CDRL2:EDNQRPS
[0127] The amino acid sequence of SEQ ID NO: 19 is as follows:
[0128] CDRL3:QSYDSSNVV
[0129] The amino acid sequence of SEQ ID NO:20 is as follows:
[0130] CDRH1:TYAIS
[0131] The amino acid sequence of SEQ ID NO:21 is as follows:
[0132] CDRH2: WITTYEGNTHYAPKFHG
[0133] The amino acid sequence of SEQ ID NO:22 is as follows:
[0134] CDRH3:HNYEMNWTFQDY
[0135] The amino acid sequence of SEQ ID NO:23 is as follows:
[0136] CDRL1:SGSSSNIGSNSVD
[0137] The amino acid sequence of SEQ ID NO:24 is as follows:
[0138] CDRL2: NNNQRPS
[0139] The amino acid sequence of SEQ ID NO:25 is as follows:
[0140] CDRL3:AAWDDSLNGLV
[0141] The amino acid sequence of SEQ ID NO:26 is as follows:
[0142] CDRH1:TSGVGVG
[0143] The amino acid sequence of SEQ ID NO:27 is as follows:
[0144] CDRH2:LIYWDDDKHYRPSLES
[0145] The amino acid sequence of SEQ ID NO:28 is as follows:
[0146] CDRH3:RLYYDSSGYYKTFDI
[0147] The amino acid sequence of SEQ ID NO:29 is as follows:
[0148] CDRL1:TLSSEHSTYTIE
[0149] The amino acid sequence of SEQ ID NO:30 is as follows:
[0150] CDRL2:VKSDGSHIKGD
[0151] The amino acid sequence of SEQ ID NO:31 is as follows:
[0152] CDRL3:GESHTIDGQVGYV
[0153] The amino acid sequence of SEQ ID NO:32 is as follows:
[0154] CDRH1: SNSAAWN
[0155] The amino acid sequence of SEQ ID NO:33 is as follows:
[0156] CDRH2:RTYYRSKWYYDYAVSLKS
[0157] The amino acid sequence of SEQ ID NO:34 is as follows:
[0158] CDRH3: NYAFDF
[0159] The amino acid sequence of SEQ ID NO:35 is as follows:
[0160] CDRL1:SGSSSNIGSHYVF
[0161] The amino acid sequence of SEQ ID NO:36 is as follows:
[0162] CDRL2:SNDQRPS
[0163] The amino acid sequence of SEQ ID NO:37 is as follows:
[0164] CDRL3:VAWDGGLRNYV
[0165] The amino acid sequence of SEQ ID NO:38 is as follows:
[0166] QVQLQESGSGLVKPSQTLSLTCAVSGGSISSTGYSWSWIRQPPGRGLEWIGNIYHSGSTYYNPSLESRVTISSVDTSKNQFSLKLSSVTAADTAVYYCARQGGSSSSWYYYYMDVWGKGTMVTVSS
[0167] The amino acid sequence of SEQ ID NO:39 is as follows:
[0168] QSVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG
[0169] The amino acid sequence of SEQ ID NO:40 is as follows:
[0170] QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTTVYYCARELGSTGAYYYYGMDVWGQGTMVTVSS
[0171] The amino acid sequence of SEQ ID NO:41 is as follows:
[0172] QAVLTQPPSASGTPGQRVTISSCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTKLTVLG
[0173] The amino acid sequence of SEQ ID NO:42 is as follows:
[0174] QVQLVQSGGGLVKPGGSLRLSCAASGFTFSGSAMHWVRQASGKGLEWVGRIRSKANSYATAYAASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCSRVNSGYYGPDYWGKGTLVTVSS
[0175] The amino acid sequence of SEQ ID NO:43 is as follows:
[0176] LNFMLTQPHSVSGSPGKTVTISCTRNGGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDRSSNSASLTISGLTDDDEADYYCQSYDSSNVVFGGGTQLTVLS
[0177] The amino acid sequence of SEQ ID NO:44 is as follows:
[0178] EVQLVQSGAEVKRPGSSVKVSCKASGDTFSTYAISWVRQAPGQGLEWMGWITTYEGNTHYAPKFHGRVTMTTDTSSTAYMELRSLRSDDTAIYYCARHNYEMNWTFQDYWGRGTMVTVSS
[0179] The amino acid sequence of SEQ ID NO:45 is as follows:
[0180] LSSELTQPPSASGTPGQRVTISSCSGSSSNIGSNSVDWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGLVFGGGTKVTVLS
[0181] The amino acid sequence of SEQ ID NO:46 is as follows:
[0182] QVTLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKHYRPSLESRLTIARDTSKNQVVLTMTNMDPVDTATYYCARRLYYDSSGYYKTFDIWGKGTMVTVSS
[0183] The amino acid sequence of SEQ ID NO:47 is as follows:
[0184] QPVLTQPPSASALLGASIKLTCTLSSEHSTYTIEWYQQRPGGSPQYIMKVKSDGSHIKGDGIPDRRFMGSSSGADRYLTLSNVQSDDEAEYHCGESHTIDGQVGYVFGTGTKLTVLG
[0185] The amino acid sequence of SEQ ID NO:48 is as follows:
[0186] QVQLQQSGPGLVKPSQTLSLTCAISGDSISSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYYDYAVSLKSRMTINPDTSKNQFSLQLNSVTPEDTAVYYCARNYAFDFWGQGTTVTVSS
[0187] The amino acid sequence of SEQ ID NO:49 is as follows:
[0188] QSALTQPPSVSGTPGQTVTISCSGSSSNIGSHYVFWFQRVPGMAPKLLIYSNDQRPSGVPDRFSGSKSGTSASLTISGLRSEDEADYYCVAWDGGLRNYVFGSGTKVTVLG
[0189] For example, when the antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 80% identical to the CDR, respectively, it may comprise an amino acid sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical or 100% identical to the CDR, respectively;
[0190] When the antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 80% identical to the heavy chain variable region amino acid sequence and the light chain variable region amino acid sequence, respectively, it may comprise an amino acid sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical or 100% identical to the heavy chain variable region amino acid sequence and the light chain variable region amino acid sequence, respectively.
[0191] In some embodiments, the antibody is a 2C12 antibody, a 2G10 antibody, a 2B7 antibody, a 2A4 antibody, a 2H2 antibody, or a 1H11 antibody.
[0192] When the antibody comprises an amino acid sequence of SEQ ID NO: 2-7 in the complementary determining region, it is a 2C12 antibody;
[0193] When the antibody comprises an amino acid sequence of SEQ ID NOs: 8-13 in the complementary determining region, it is a 2G10 antibody;
[0194] When the antibody comprises an amino acid sequence of SEQ ID NOs: 14-19 in the complementary determining region, it is a 2B7 antibody;
[0195] When the antibody comprises an amino acid sequence of SEQ ID NOs: 20-25 in the complementary determining region, it is a 2A4 antibody;
[0196] When the antibody comprises an amino acid sequence of SEQ ID NOs: 26-31 in the complementary determining region, it is a 2H2 antibody;
[0197] When the antibody comprises an amino acid sequence of SEQ ID NO:32-37 in the complementary determining region, it is a 1H11 antibody;
[0198] When the antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NOs: 38-39, respectively, it is a 2C12 antibody;
[0199] When the antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NOs: 40-41, respectively, it is a 2G10 antibody;
[0200] When the antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NOs: 42-43, respectively, it is a 2B7 antibody;
[0201] When the antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NOs: 44-45, respectively, it is a 2A4 antibody;
[0202] When the antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NOs: 46-47, respectively, it is a 2H2 antibody;
[0203] When the antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NOs: 48-49, respectively, it is a 1H11 antibody.
[0204] In some embodiments, the heavy chain of the 2C12 antibody comprises the amino acid sequence shown in SEQ ID NO:50 or is SEQ ID NO:50 and the light chain of the 2C12 antibody comprises the amino acid sequence shown in SEQ ID NO:51 or is SEQ ID NO:51.
[0205] The amino acid sequence of SEQ ID NO:50 is as follows:
[0206] QVQLQESGSGLVKPSQTLSLTCAVSGGSISSTGYSWSWIRQPPGRGLEWIGNIYHSGSTYYNPSLESRVTISSVDTSKNQFSLKLSSVTAADTAVYYCARQGGSSSSWYYYYMD VWGKGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0207] The amino acid sequence of SEQ ID NO:51 is as follows:
[0208] QSVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKL TVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC
[0209] In some embodiments, the heavy chain of the 2G10 antibody comprises the amino acid sequence shown in SEQ ID NO:52 or is SEQ ID NO:52, and the light chain of the 2G10 antibody comprises the amino acid sequence shown in SEQ ID NO:53 or is SEQ ID NO:53.
[0210] The amino acid sequence of SEQ ID NO:52 is as follows:
[0211] QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTTVYYCARELGSTGAYYYYGMDV WGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0212] The amino acid sequence of SEQ ID NO:53 is as follows:
[0213] QAVLTQPPSASGTPGQRVTISSCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTKL TVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC
[0214] In some embodiments, the heavy chain of the 2B7 antibody comprises the amino acid sequence shown in SEQ ID NO:54 or is SEQ ID NO:54, and the light chain of the 2B7 antibody comprises the amino acid sequence shown in SEQ ID NO:55 or is SEQ ID NO:55.
[0215] The amino acid sequence of SEQ ID NO:54 is as follows:
[0216] QVQLVQSGGGLVKPGGSLRLSCAASGFTFSGSAMHWVRQASGKGLEWVGRIRSKANSYATAYAASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCSRVNSGYYGPDYWG KGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0217] The amino acid sequence of SEQ ID NO:55 is as follows:
[0218] LNFMLTQPHSVSGSPGKTVTISCTRNGGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDRSSNSASLTISGLTDDDEADYYCQSYDSSNVVFGGGTQL TVLSQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC
[0219] In some embodiments, the heavy chain of the 2A4 antibody comprises the amino acid sequence shown in SEQ ID NO:56 or is SEQ ID NO:56, and the light chain of the 2A4 antibody comprises the amino acid sequence shown in SEQ ID NO:57 or is SEQ ID NO:57.
[0220] The amino acid sequence of SEQ ID NO:56 is as follows:
[0221] EVQLVQSGAEVKRPGSSVKVSCKASGDTFSTYAISWVRQAPGQGLEWMGWITTYEGNTHYAPKFHGRVTMTTDTSSTAYMELRSLRSDDTAIYYCARHNYEMNWTFQDYWG RGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0222] The amino acid sequence of SEQ ID NO:57 is as follows:
[0223] LSSELTQPPSASGTPGQRVTISSCSGSSSNIGSNSVDWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGLVFGGGTKV TVLSQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC
[0224] In some embodiments, the heavy chain of the 2H2 antibody comprises the amino acid sequence shown in SEQ ID NO:58 or is SEQ ID NO:58, and the light chain of the 2H2 antibody comprises the amino acid sequence shown in SEQ ID NO:59 or is SEQ ID NO:59.
[0225] The amino acid sequence of SEQ ID NO:58 is as follows:
[0226] QVTLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKHYRPSLESRLTIARDTSKNQVVLTTMTNMDPVDTATYYCARRLYYDSSGYYKTFD IWGKGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0227] The amino acid sequence of SEQ ID NO:59 is as follows:
[0228] QPVLTQPPSASALLGASIKLTCTLSSEHSTYTIEWYQQRPGGSPQYIMKVKSDGSHIKGDGIPDRRFMGSSSGADRYLTLSNVQSDDEAEYHCGESHTIDGQVGYVFGTGT KLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC
[0229] In some embodiments, the heavy chain of the 1H1 antibody comprises the amino acid sequence shown in SEQ ID NO:60 or is SEQ ID NO:60, and the light chain of the 1H1 antibody comprises the amino acid sequence shown in SEQ ID NO:61 or is SEQ ID NO:61.
[0230] The amino acid sequence of SEQ ID NO:60 is as follows:
[0231] QVQLQQSGPGLVKPSQTLSLTCAISGDSISSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYYDYAVSLKSRMTINPDTSKNQFSLQLNSVTPEDTAVYYCARNYAFDFWGQGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0232] The amino acid sequence of SEQ ID NO:61 is as follows:
[0233] QSALTQPPSVSGTPGQTVTISCSGSSSNIGSHYVFWFQRVPGMAPKLLIYSNDQRPSGVPDRFSGSKSGTSASLTISGLRSEDEADYYCVAWDGGLRNYVFGSGTKVT VLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC.
[0234] In some embodiments, the antibody or antigen-binding fragment thereof specifically binds to human V-domain Ig inhibitory factor of T cell activation (VISTA), and preferably, the amino acid sequence of the VISTA antigen comprises the amino acid sequence shown in SEQ ID NO: 1 or is SEQ ID NO: 1.
[0235] The amino acid sequence of SEQ ID NO: 1 is as follows:
[0236] MGVPTALEGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAA
[0237] In some embodiments, the antibody or its antigen-binding fragment is a monoclonal antibody, a recombinant antibody, a fully human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antigen-binding fragment of these antibodies. In some embodiments, the antibody or its antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, or a scFv fragment. In some embodiments, the antibody or its antigen-binding fragment comprises the constant domain of human IgG1, IgG2, IgG3, or IgG4.
[0238] In some embodiments, the anti-VISTA antibody or antigen-binding fragment thereof comprises a complementary determining region (CDR) sequence selected from the following: SEQ ID NO: 2-37, or comprises an amino acid sequence having at least 80% identity with the complementary determining region sequence, respectively. In some embodiments, the complementary determining region comprises a heavy chain complementary determining region and a complementary determining region;
[0239] The heavy chain complementarity determining region is:
[0240] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:2, a CDR2 having an amino acid sequence as shown in SEQ ID NO:3, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:4;
[0241] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:8, a CDR2 having an amino acid sequence as shown in SEQ ID NO:9, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:10;
[0242] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 14, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 15, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 16;
[0243] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:20, a CDR2 having an amino acid sequence as shown in SEQ ID NO:21, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:22;
[0244] comprising a CDR1 of the amino acid sequence shown in SEQ ID NO:26, a CDR2 of the amino acid sequence shown in SEQ ID NO:27, and a CDR3 of the amino acid sequence shown in SEQ ID NO:28; or
[0245] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:32, a CDR2 having an amino acid sequence as shown in SEQ ID NO:33, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:34;
[0246] The light chain complementarity determining region is
[0247] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:5, a CDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:7;
[0248] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 11, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 12, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 13;
[0249] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 17, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 18, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 19;
[0250] comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO:23, a CDR2 having an amino acid sequence as shown in SEQ ID NO:24, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:25;
[0251] comprising a CDR1 of the amino acid sequence shown in SEQ ID NO:29, a CDR2 of the amino acid sequence shown in SEQ ID NO:30, and a CDR3 of the amino acid sequence shown in SEQ ID NO:31; or
[0252] comprising CDR1 of the amino acid sequence shown in SEQ ID NO:35, CDR2 of the amino acid sequence shown in SEQ ID NO:36, and CDR3 of the amino acid sequence shown in SEQ ID NO:37. In some embodiments, the heavy chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO:2, CDR2 of the amino acid sequence shown in SEQ ID NO:3, and CDR3 of the amino acid sequence shown in SEQ ID NO:4, and the light chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO:5, CDR2 of the amino acid sequence shown in SEQ ID NO:6, and CDR3 of the amino acid sequence shown in SEQ ID NO:7;
[0253] The heavy chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO:8, CDR2 of the amino acid sequence shown in SEQ ID NO:9, and CDR3 of the amino acid sequence shown in SEQ ID NO:10, and the light chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO:11, CDR2 of the amino acid sequence shown in SEQ ID NO:12, and CDR3 of the amino acid sequence shown in SEQ ID NO:13;
[0254] The heavy chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO: 14, CDR2 of the amino acid sequence shown in SEQ ID NO: 15, and CDR3 of the amino acid sequence shown in SEQ ID NO: 16, and the light chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO: 17, CDR2 of the amino acid sequence shown in SEQ ID NO: 18, and CDR3 of the amino acid sequence shown in SEQ ID NO: 19;
[0255] The heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:20, CDR2 of the amino acid sequence shown in SEQ ID NO:21, and CDR3 of the amino acid sequence shown in SEQ ID NO:22, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:23, CDR2 of the amino acid sequence shown in SEQ ID NO:24, and CDR3 of the amino acid sequence shown in SEQ ID NO:25;
[0256] The heavy chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:26, CDR2 of the amino acid sequence shown in SEQ ID NO:27, and CDR3 of the amino acid sequence shown in SEQ ID NO:28, and the light chain complementary determining regions are CDR1 of the amino acid sequence shown in SEQ ID NO:29, CDR2 of the amino acid sequence shown in SEQ ID NO:30, and CDR3 of the amino acid sequence shown in SEQ ID NO:31; or
[0257] The heavy chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO:32, CDR2 of the amino acid sequence shown in SEQ ID NO:33, and CDR3 of the amino acid sequence shown in SEQ ID NO:34, and the light chain complementary determining region is CDR1 of the amino acid sequence shown in SEQ ID NO:35, CDR2 of the amino acid sequence shown in SEQ ID NO:36, and CDR3 of the amino acid sequence shown in SEQ ID NO:37. In some embodiments, the antibody or antigen-binding fragment thereof comprises a human framework region amino acid sequence, preferably, the human framework region amino acid sequence is a human consensus framework region amino acid sequence. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence selected from the following: SEQ ID NO:38-49, or comprises an amino acid sequence having at least 80% identity with the heavy chain variable region amino acid sequence and the light chain variable region amino acid sequence, respectively. In some embodiments, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:38, the amino acid sequence shown in SEQ ID NO:40, the amino acid sequence shown in SEQ ID NO:42, the amino acid sequence shown in SEQ ID NO:44, the amino acid sequence shown in SEQ ID NO:46, or the amino acid sequence shown in SEQ ID NO:48; and / or
[0258] The light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 39, the amino acid sequence shown in SEQ ID NO: 41, the amino acid sequence shown in SEQ ID NO: 43, the amino acid sequence shown in SEQ ID NO: 45, the amino acid sequence shown in SEQ ID NO: 47, or the amino acid sequence shown in SEQ ID NO: 49. In some embodiments, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 38 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 39; or
[0259] The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:40 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:41; or
[0260] The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:42 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:43; or
[0261] The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:44 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:45; or
[0262] The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:46 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:47; or
[0263] The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:48 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:49. In some embodiments, the antibody or its antigen-binding fragment is a monoclonal antibody, a recombinant antibody, a fully human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antigen-binding fragment of these antibodies. In some embodiments, the antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, or a scFv fragment. In some embodiments, the antibody or its antigen-binding fragment comprises the constant domain of human IgG1, IgG2, IgG3, or IgG4.
[0264] Polynucleotides, expression vectors and host cells
[0265] The present application provides a polynucleotide encoding the above-mentioned antibody or antigen-binding fragment thereof. The present application provides an expression vector comprising the above-mentioned polynucleotide. The present application provides a host cell comprising the above-mentioned expression vector. The present application provides a method for preparing the antibody or antigen-binding fragment thereof, comprising: culturing the above-mentioned host cell and recovering the antibody or antigen-binding fragment thereof from the cultured host cell.
[0266] The polynucleotides include DNA (gDNA and cDNA) and RNA molecules, as well as nucleotides, which are the basic building blocks of polynucleotides, including nucleotides of natural origin and analogs of modified sugar or base moieties. The sequences of the polynucleotides encoding the heavy and light chain variable regions of the present application can be changed. Such variations include additions, deletions, or non-conservative or conservative substitutions of nucleotides.
[0267] DNA encoding the antibodies or antigen-binding fragments thereof can be readily isolated or synthesized using conventional procedures (eg, using oligonucleotide probes that are capable of binding specifically to DNA encoding the antibody heavy and light chains).
[0268] The expression vector refers to a tool for expressing a target gene in a host cell, and includes plasmid vectors, cosmid vectors and viral vectors, such as phage vectors, adenoviral vectors, retroviral vectors and adeno-associated viral vectors, etc. The nucleic acid encoding the antibody or antigen-binding fragment thereof in the expression vector is operably linked to a promoter.
[0269] The host cell is a host cell used to produce the antibody or antigen-binding fragment thereof described in the present application. The host cell used to produce the antibody or antigen-binding fragment thereof may be a prokaryotic organism, yeast or higher eukaryotic cell, but is not limited thereto. The prokaryotic host cells that can be used include, for example, Escherichia coli; Bacillus strains such as Bacillus subtilis and Bacillus thuringiensis; Streptomyces species; Pseudomonas species (e.g., Pseudomonas putida); Proteus mirabilis; and Staphylococcus species (e.g., Staphylococcus carnosus). Animal cells that can be used include, but are not limited to, COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER .C6, SP2 / 0, NS-0, U20S and HT1080.
[0270] In the present application, for culturing host cells, host cells can be cultured in various culture media. Any commercially available culture media can be used as culture media. All other necessary supplements well known to those skilled in the art can be added at appropriate concentrations. For culture conditions such as temperature and pH value, all are culture conditions conventional in the art, and those skilled in the art can make conventional selections as needed.
[0271] The antibody or antigen-binding fragment thereof can be recovered by, for example, centrifugation or ultrafiltration to remove impurities, and the resulting product can be purified using, for example, affinity chromatography. Other purification techniques, such as anion or cation exchange chromatography, hydrophobic interaction chromatography, and hydroxyapatite (HA) chromatography, etc., can also be used.
[0272] Pharmaceutical composition
[0273] The present application provides a pharmaceutical composition, which comprises the above-mentioned antibody or antigen-binding fragment thereof and a pharmaceutically acceptable excipient.
[0274] The antibodies or antigen-binding fragments thereof described in the present application can be formulated into pharmaceutical compositions by combining with suitable pharmaceutically acceptable carriers or diluents, and can be formulated into preparations in solid, semi-solid, liquid or gaseous forms, for example, tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols, etc.
[0275] In a pharmaceutical dosage form, the antibody or antigen-binding fragment thereof may be administered in combination with a pharmaceutically acceptable excipient, or may be used alone or in appropriate combination with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are by no means limiting.
[0276] The antibody or antigen-binding fragment thereof can be formulated into an injection preparation by dissolving, suspending or emulsifying in water or a non-aqueous solvent (e.g., vegetable oil or other similar oils, synthetic fatty acid glycerides, higher fatty acid esters or propylene glycol); if necessary, conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives can also be added.
[0277] Pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof are prepared by mixing an antibody or antigen-binding fragment thereof of the desired purity with optional physiologically acceptable excipients (e.g., carriers, excipients, stabilizers, surfactants, buffers and / or tonicity agents). Acceptable carriers, excipients and / or stabilizers are non-toxic to the receptor at the doses and concentrations used. Acceptable carriers, excipients and / or stabilizers include buffers such as phosphates, citrates and other organic acids; antioxidants including ascorbic acid, glutathione, cysteine, methionine and citric acid; preservatives (e.g., ethanol, benzyl alcohol, phenol, m-cresol, p-chloro-m-cresol, methyl or propyl paraben, benzalkonium chloride or a combination thereof); amino acids (e.g., arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof); monosaccharides, disaccharides and other carbohydrates; low molecular weight (less than about 10 residues) polypeptides; proteins (e.g., gelatin or serum albumin); chelating agents such as EDTA; sugars such as trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbitol, raffinose, glucosamine, N-methylglucosamine, galactosamine, neuraminic acid, etc.; and / or non-ionic surfactants such as Tween, BrijPluronics, Triton-X or polyethylene glycol (PEG).
[0278] The pharmaceutical composition may be in liquid form, lyophilized form, or liquid form reconstituted in lyophilized form, wherein the lyophilized preparation is reconstituted with a sterile solution prior to administration.
[0279] Therapeutic applications
[0280] The present application provides a method for treating a subject suffering from a VISTA-mediated disease, the method comprising administering to the subject an effective amount of the above-described antibody or antigen-binding fragment thereof or the above-described pharmaceutical composition. In some embodiments, the VISTA-mediated disease is leukemia, lymphoma, myelodysplasia, myeloma, or a combination thereof.
[0281] The present application provides the use of the above-mentioned antibody or its antigen-binding fragment or the above-mentioned pharmaceutical composition in the preparation of a drug for treating a disease related to VISTA mediation. The present application also provides the use of the above-mentioned antibody or its antigen-binding fragment or the above-mentioned pharmaceutical composition for treating a disease related to VISTA mediation. In some embodiments, the disease related to VISTA mediation is leukemia, lymphoma, myelodysplasia, myeloma or a combination thereof.
[0282] The antibodies or antigen-binding fragments thereof and pharmaceutical compositions described herein can be used for a variety of different subjects, including but not limited to mammals, humans, non-human mammals, domestic animals (e.g., laboratory animals, household pets or livestock), non-domestic animals (e.g., wild animals), dogs, cats, rodents, mice, hamsters, cows, birds, chickens, fish, pigs, horses, goats, sheep, rabbits and any combination thereof. In some embodiments, the subject is a human.
[0283] The antibody or its antigen-binding fragment and its pharmaceutical composition of the present application can be used as a therapeutic agent, for example, a therapeutic product that can be applied to a subject in need. The therapeutic effect of the antibody or its antigen-binding fragment and its pharmaceutical composition of the present application can be obtained in the subject by reducing, suppressing, alleviating or eradicating the disease state (including but not limited to its symptoms). The therapeutic effect in a subject suffering from a disease or susceptible to or just beginning to suffer from a disease or condition can be obtained by reducing, suppressing, preventing, alleviating or eradicating the condition or disease or pre-condition or pre-disease state.
[0284] The antibody or its antigen-binding fragment or its pharmaceutical composition of the present application of an effective amount or dosage to the subject can be carried out by one or more routes, and can occur once or multiple times within a given time period. It will be understood by those of ordinary skill in the art that the application of the conjugate of the present application or its pharmaceutical composition to the subject in need, the duration and frequency of application depend on several factors, including, for example, the health status of the subject, the specific disease or condition of the subject, the grade or level of the specific disease or condition of the subject, the additional treatment that the subject is receiving or has received, etc. Exemplary routes of administration include systemic, skin, subcutaneous, intravenous, intraarterial, subdural, intramuscular, intracranial, intrasternal, intratumoral, intraperitoneal. In addition, the conjugate of the present application or its pharmaceutical composition can be applied to the subject by other routes of administration, such as by inhalation, or oral, skin, intranasal or intrathecal administration.
[0285] The antibodies or antigen-binding fragments thereof and pharmaceutical compositions described herein can be administered to a subject in need in the first administration, and then administered to a subject in need in one or more additional administrations. One or more additional administrations can be administered to a subject in need a few minutes, hours, days, weeks, or months after the first administration. Any of the additional administrations can be administered to a subject in need less than 21 days, or less than 14 days, less than 10 days, less than 7 days, less than 4 days, or less than 1 day after the first administration. One or more administrations can occur more than once a day, more than once a week, or more than once a month. Administration can be once a week, biweekly / every two weeks, once every three weeks, once a month, or once every two months.
[0286] Example
[0287] The present application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % means wt%, i.e., weight percentage. The reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially.
[0288] Example 1 Preparation of Antibodies
[0289] The Human VISTA (M1-A194)-Fc sequence (Nishant Mehta1, et al., 2021.) was selected as the antibody screening antigen (abbreviated as hVISTA-Fc). The hVISTA-Fc sequence was first synthesized and plasmid constructed, then transiently expressed using ExpiCHO-S™ cells (manufacturer: ThermoFisher), and the antigen protein was obtained by Protein A affinity chromatography.
[0290] Using hVISTA-Fc as the target antigen, two antibody libraries, scfv-κ 190625 and scfv-λ190718, were screened. The two antibody libraries were subjected to "binding-elution-amplification" respectively, and positive clones were screened out after three rounds of solid phase panning and monoclonal ELISA identification. The Scfv sequence of the positive clone was transformed into human IgG1 format, and gene synthesis and vector construction were performed. The obtained plasmid expressed the antibody according to the transient transfection method provided by the CHO-S cell manufacturer. The cell culture supernatant was purified by Protein A affinity chromatography (manufacturer: Cytiva). The obtained samples were tested for purity by SDS-PAGE and SEC-HPLC methods. After passing the test, subsequent antibody evaluation experiments were carried out, and the results were as follows: Figure 1A and Figure 1B shown.
[0291] from Figure 1A and Figure 1B It can be seen that the 2C12 antibody, 2G10 antibody, 2B7 antibody, 2A4 antibody, 2H2 antibody or 1H11 antibody obtained through screening can all be correctly expressed, which is consistent with the expected theory.
[0292] Example 2 ELISA binding activity test of anti-VISTA antibodies and human VISTA antigen
[0293] Human hVISTA-Fc was diluted to 10 μg / ml with coating solution, 50 μl / well was added to a 96-well plate, coated at 37°C for 2 h, and after washing, 200 μl of 5% skim milk powder was added to each well and blocked at 4°C overnight.
[0294] The antibodies prepared in Example 1 were diluted to 100 μg / ml with PBS, and then diluted to 10 μg / ml with 5% skim milk powder as the starting concentration. Each antibody was diluted 10 times in sequence, with a total of 8 dilution gradients, and blocked at 37°C for 0.5h. After washing the plate, the blocked antibody was transferred to the ELISA test plate coated with the antigen, 50 μl / well, and incubated at 37°C for 1h. After washing the plate, 1 μl of secondary antibody (manufacturer: Jacson ImmunoResearch) was added to 5 ml 5% skim milk powder, diluted 1:5000, mixed, and 50 μl of diluted secondary antibody was added to each well, and incubated at 37°C for 0.5h. 50 μl of TMB colorimetric solution (manufacturer: KPL) was added to each well, and the color was developed at room temperature for about 5 minutes until the positive control was obviously colored, and 50 μl of stop solution was added to each well to stop the color development. The reading value was detected by the ELISA reader at a wavelength of 450nm. The binding activity results are as follows Figure 2 shown.
[0295] from Figure 2 It can be seen that the obtained 2C12 antibody and 2A4 antibody have good binding activity with the human VISTA antigen.
[0296] Example 3 Anti-VISTA antibody-mediated HL-60 cell endocytosis activity test
[0297] The antibody prepared in Example 1 was fluorescently labeled with Alexa Fluor™ 647 (manufacturer: ThermoFisher). HL-60 cells (manufacturer: ATCC) were plated in 96-well plates at a cell density of 1×10 6 cells / mL, the culture medium was 80% IMDM + 20% FBS + 1% antibiotics. Alexa Fluor™ 647 fluorescently labeled anti-VISTA antibody was added 2h after plating, making the final concentration of the antibody 4μg / mL. Flow cytometry fluorescence sorting technology (FACS) detection was performed 1 h and 24 h after adding the antibody, respectively, with an excitation wavelength of 638nm and a fluorescence detection channel of 660nm. The test results are shown in Figure 3A and 3B As shown, Figure 3A This is a flow cytometry fluorescence sorting detection diagram of fluorescently labeled anti-VISTA antibody and HL-60 cells incubated for 1 hour. Figure 3B This is a flow cytometry fluorescence sorting detection diagram of HL-60 cells incubated with fluorescently labeled anti-VISTA antibodies for 24 hours.
[0298] from Figure 3A and Figure 3B It can be seen that at 1h, 2C12 antibody has good HL-60 cell endocytosis activity, and its intracellular average fluorescence intensity is the highest. At 24h, 2C12, 2A4 and 2H2 antibodies all show good cell endocytosis activity.
[0299] Example 4 Fluorescence detection of anti-VISTA antibody-mediated endocytosis in HL-60 cells
[0300] The antibody prepared in Example 1 was fluorescently labeled with Alexa Fluor™594 (manufacturer: ThermoFisher). HL-60 cells were plated in 96-well plates at a cell density of 1×10 6 cells / mL, the culture medium was 80% IMDM + 20% FBS + 1% antibiotics. Alexa Fluor™ 594 fluorescently labeled anti-VISTA antibody was added 2h after plating, making the final concentration of the antibody 4μg / mL. VISTA antibody internalization into HL-60 cells was observed by fluorescence microscopy 24h after adding the antibody. The test results are as follows Figure 4 As shown, Figure 4 The arrows indicate red fluorescent signals.
[0301] from Figure 4 It can be seen that after 24 hours of incubation of antibodies and HL-60, no significant red fluorescence signal was observed in the cells with 1H11, indicating that it could not be internalized into the cells. However, after incubation of 2C12, 2A4 and 2H2 with HL-60 cells, red fluorescence signals of different intensities appeared, indicating that these antibodies could be internalized into the cells, and 2C12 had better internalization activity.
[0302] The above is only the preferred embodiment of the present application, and does not limit the present application in other forms. Any technician familiar with the profession may use the above disclosed technical content to change or modify it into an equivalent embodiment with equivalent changes. However, any simple modification, equivalent change and modification made to the above embodiment based on the technical essence of the present application without departing from the technical solution of the present application still falls within the protection scope of the technical solution of the present application.
Claims
1. An anti-VISTA antibody or an antigen-binding fragment thereof, comprising a heavy chain complementary determining region and a light chain complementary determining region as shown below: The heavy chain complementary determining region comprises CDR1 of the amino acid sequence shown in SEQ ID NO:2, CDR2 of the amino acid sequence shown in SEQ ID NO:3, and CDR3 of the amino acid sequence shown in SEQ ID NO:4, and the light chain complementary determining region comprises CDR1 of the amino acid sequence shown in SEQ ID NO:5, CDR2 of the amino acid sequence shown in SEQ ID NO:6, and CDR3 of the amino acid sequence shown in SEQ ID NO:
7.
2. The antibody or antigen-binding fragment thereof according to claim 1, comprising a human framework region amino acid sequence.
3. The antibody or antigen-binding fragment thereof according to claim 2, wherein the human framework region amino acid sequence is a human consensus framework region amino acid sequence.
4. The antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 38 or an amino acid sequence having at least 80% identity with the amino acid sequence; and / or The light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 39 or an amino acid sequence that is at least 80% identical to the amino acid sequence.
5. The antibody or antigen-binding fragment thereof according to claim 4, wherein: The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 38 and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 39, or an amino acid sequence that has at least 80% identity with each of the amino acid sequences.
6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein The antibody or antigen-binding fragment thereof is a monoclonal antibody, a recombinant antibody, a fully human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody or an antigen-binding fragment thereof.
7. The antibody or antigen-binding fragment thereof according to claim 6, wherein The antigen binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment or a scFv fragment.
8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein The antibody or antigen-binding fragment thereof comprises the constant domain of human IgG1, IgG2, IgG3 or IgG4.
9. A polynucleotide encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
10. An expression vector comprising the polynucleotide of claim 9. A host cell comprising the expression vector according to claim 10.
12. The host cell according to claim 11, wherein The host cell is a prokaryotic cell or a eukaryotic cell.
13. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, comprising: (a) culturing the host cell according to claim 11 or 12; as well as (b) recovering the antibody or antigen-binding fragment thereof from the cultured host cells.
14. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 and a pharmaceutically acceptable excipient.
15. A conjugate comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
16. A fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
17. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, the pharmaceutical composition according to claim 14, the conjugate according to claim 15, or the fusion protein according to claim 16 in the preparation of a medicament for treating VISTA-mediated related diseases.
18. The use according to claim 17, wherein The VISTA-mediated related diseases are leukemia, lymphoma, myelodysplasia, myeloma or a combination thereof.
